GENinCode Plc

GENI

GB00BL97B504

Medical Equipment, Supplies & Distribution

Market Closed - London S.E. Other stock markets 11:35:13 2026-01-20 am EST			5-day change	1st Jan Change
1.900 ^GBX	0.00%		0.00%	-20.83%

Dec. 17	GENinCode collaborates with Sohin Genetics for heart disease test	AN
Dec. 17	GENinCode, Sohin Genetics Sign Deal to Distribute Heart Disease Test	MT

GENinCode Partners with US-based Thermo Fisher to Commercialize Heart Disease Test

Published on 12/04/2025 at 07:35 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about GENinCode Plc

Dec. 17	GENinCode collaborates with Sohin Genetics for heart disease test	AN
Dec. 17	GENinCode, Sohin Genetics Sign Deal to Distribute Heart Disease Test	MT
Dec. 17	GENinCode plc Announces Collaboration with Sohin Genetics, Mexico to Distribute the Cardio inCode-Score Polygenic Risk Score Test for the Prevention of Coronary Heart Disease	CI
Dec. 04	GENinCode inks commercialisation deal with Thermo Fisher	AN
Dec. 04	GENinCode Partners with US-based Thermo Fisher to Commercialize Heart Disease Test	MT
Dec. 04	Stocks climb but construction activity sinks	AN
Dec. 04	AIM WINNERS & LOSERS: GENinCode strikes deal; Metals One falls	AN
Dec. 04	Genincode collaborates with Thermo Fisher	RE
Dec. 04	GENinCode plc Announces Collaboration with Thermo Fisher Scientific to Sell, Distribute and Manufacture the Cardio inCode-Score Polygenic Risk Score Test for the Predication and Prevention of Coronary Heart Disease	CI
Dec. 03	GENinCode shares soar on New York heart health test approval	AN
Dec. 03	GENinCode Gets New York State Approval for Coronary Heart Disease Test	MT
Dec. 03	FTSE 100 falls despite gains in Europe	AN
Dec. 03	AIM WINNERS & LOSERS: GENinCode jumps; Physiomics CEO to step down	AN
Dec. 03	GENinCode plc Announces New York State Clinical Test Approval of Cardio Incode-Score	CI
25-10-27	GENinCode plc Announces the Publication of Major Clinical Study in JACC: Advances Evaluating the Company's Cardio InCode-Score®? Polygenic Risk Score for Coronary Heart Disease	CI
25-10-02	GENinCode Plc, H1 2025 Earnings Call, Oct 02, 2025
25-10-01	EARNINGS: Next 15 profit falls; 4basebio and Mollyroe losses widen	AN
25-09-30	GENinCode Plc Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-09-30	EARNINGS: GENinCode sees annual revenue growth slower than expected	AN
25-09-30	Genincode says revenue for FY is likely to be lower than expected	RE
25-09-30	Earnings Flash (GENI.L) GENinCode Reports H1 Revenue GBP1.6M	MT
25-09-30	GENinCode Plc Provides Revenue Guidance for the Second Half and Full Year 2025	CI
25-09-25	GENinCode Launches Ovarian Cancer Risk Surveillance Test	MT
25-09-17	GENinCode has no explanation for share movement, reaffirms position	AN
25-09-17	GENinCode Says Unaware of Reason Behind Share Price Surge	MT

GENinCode Plc is a United Kingdom-based polygenics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict cardiovascular disease. The Company's core products include Cardio inCode - Score and Check - Coronary predictive/risk assessment; Thrombo inCode - Hematology, Recurrent Pregnancy Loss and Oncology, Thrombosis (blood clots) predictive/risk assessment; Lipid inCode - Familial Hypercholesterolemia Diagnosis and risk stratification, and SudD inCode - Hereditary Cardiomiopathies diagnosis, Risk assessment for sudden cardiac events.

Employees

Sector

Medical Equipment, Supplies & Distribution

Calendar

Jun. 08 - Q4 2025 Earnings Release (Projected)

More about the company